The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective
Standard
The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective. / Rieckmann, Thorsten; Kriegs, Malte.
In: CLIN TRANSL RAD ONCO, Vol. 17, 07.2019, p. 47-50.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective
AU - Rieckmann, Thorsten
AU - Kriegs, Malte
PY - 2019/7
Y1 - 2019/7
N2 - Human Papillomavirus-positive oropharyngeal cancer is a rising tumor entity with unique characteristics and favorable prognosis. Because current multimodal therapies are associated with severe toxicity, different strategies for treatment de-intensification are being tested in clinical trials. In this context two phase 3 studies, which examined the potential of the monoclonal anti-EGFR antibody cetuximab to replace concomitant cisplatin-based chemotherapy, have concordantly reported inferiority of this de-intensification approach. In this opinion article we discuss these recent negative results in the light of previous clinical and preclinical research on the combination of EGFR-inhibition and irradiation. Collectively these data question the effectiveness of EGFR-inhibition in the curative treatment of both HPV-positive and HPV-negative head and neck cancer but provide guidance for future translational research.
AB - Human Papillomavirus-positive oropharyngeal cancer is a rising tumor entity with unique characteristics and favorable prognosis. Because current multimodal therapies are associated with severe toxicity, different strategies for treatment de-intensification are being tested in clinical trials. In this context two phase 3 studies, which examined the potential of the monoclonal anti-EGFR antibody cetuximab to replace concomitant cisplatin-based chemotherapy, have concordantly reported inferiority of this de-intensification approach. In this opinion article we discuss these recent negative results in the light of previous clinical and preclinical research on the combination of EGFR-inhibition and irradiation. Collectively these data question the effectiveness of EGFR-inhibition in the curative treatment of both HPV-positive and HPV-negative head and neck cancer but provide guidance for future translational research.
U2 - 10.1016/j.ctro.2019.05.003
DO - 10.1016/j.ctro.2019.05.003
M3 - SCORING: Journal article
C2 - 31206086
VL - 17
SP - 47
EP - 50
JO - CLIN TRANSL RAD ONCO
JF - CLIN TRANSL RAD ONCO
SN - 2405-6308
ER -